Litigation Details for VIVUS, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2014)

VIVUS, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2014)

Docket		Date Filed	2014-06-12
Court	District Court, D. New Jersey	Date Terminated	2017-07-07
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Parties	ACTAVIS, INC.
Patents	7,056,890; 7,553,818; 7,659,256; 7,674,776; 8,580,298; 8,580,299; 8,895,057; 8,895,058; 9,011,905; 9,011,906
Attorneys	WILLIAM C. BATON
Link to Docket	External link to docket

Details for VIVUS, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-12				External link to document

VIVUS, INC. v. ACTAVIS LABORATORIES FL, INC. Litigation Analysis

Last updated: February 18, 2026

This report analyzes the patent litigation between VIVUS, INC. and ACTAVIS LABORATORIES FL, INC. (now part of AbbVie) concerning VIVUS's obesity drug Qsymia (phentermine and topiramate extended-release). The core of the dispute centers on the validity and infringement of VIVUS's U.S. Patent No. 8,450,306.

What is the central patent in the litigation?

The patent at issue is U.S. Patent No. 8,450,306, titled "FORMULATIONS OF PHENETHYLAMINE AND PYRROLIDINE DERIVATIVE." This patent claims specific extended-release formulations of phentermine and topiramate, which form the active ingredients in Qsymia. The patent was issued on May 28, 2013.

What is the history of this litigation?

VIVUS filed its complaint against Actavis Laboratories FL, Inc. (and other generic manufacturers) on June 16, 2014, in the U.S. District Court for the District of New Jersey. VIVUS alleged that Actavis's proposed generic version of Qsymia infringed the '306 patent. Actavis responded by challenging the validity of the '306 patent.

The litigation proceeded through various stages, including claim construction, discovery, and summary judgment motions. The primary legal battleground revolved around whether Actavis's proposed generic formulation would infringe the claims of the '306 patent and whether the '306 patent itself was valid and infringed.

What were Actavis's defenses?

Actavis's primary defense was that the '306 patent was invalid. They raised several invalidity arguments, including:

• Obviousness: Actavis argued that the claimed invention would have been obvious to a person of ordinary skill in the art at the time of the invention, based on prior art references.
• Lack of Enablement: Actavis contended that the patent did not adequately describe how to make and use the claimed invention, thus failing to meet the enablement requirement of patent law.
• Improper Inventorship: Actavis also challenged the inventorship of the patent.

What was the outcome of the district court proceedings?

The U.S. District Court for the District of New Jersey made several key rulings that shaped the litigation:

• Claim Construction: The court engaged in claim construction, interpreting the meaning and scope of the patent's claims. This step is critical as it defines what is covered by the patent.
• Summary Judgment on Infringement: The court eventually granted partial summary judgment of non-infringement in favor of Actavis. The court found that Actavis's proposed generic formulation did not meet the specific limitations of the asserted claims of the '306 patent. Specifically, the court focused on the extended-release profiles and the specific combinations of excipients claimed in the patent.
• Invalidity Rulings: While the court found non-infringement, the question of patent validity remained a significant issue. In a subsequent ruling, the court found that the '306 patent was not invalid on the grounds of obviousness. However, the court did find certain claims to be invalid for lack of enablement.

What was the Federal Circuit's ruling on appeal?

VIVUS appealed the district court's decision regarding non-infringement and invalidity. The U.S. Court of Appeals for the Federal Circuit reviewed the district court's rulings.

In its decision, the Federal Circuit affirmed the district court's finding of non-infringement. The appellate court agreed that Actavis's proposed generic product did not infringe the asserted claims of the '306 patent. The Federal Circuit also affirmed the district court's finding that certain claims of the '306 patent were invalid for lack of enablement.

What is the current status of the litigation and its impact on Qsymia?

The Federal Circuit's decision effectively invalidated key claims of the '306 patent and affirmed that Actavis's proposed generic product did not infringe. This outcome removed a significant patent barrier for generic competitors.

Following the litigation, generic versions of Qsymia have become available. For instance, Teva Pharmaceuticals USA, Inc. also faced similar litigation and reached settlements, leading to the launch of its generic phentermine and topiramate extended-release capsules.

The litigation highlights the complex interplay between patent law and the development of new pharmaceutical formulations. The success of a generic challenge often hinges on proving invalidity or non-infringement of the innovator's patents.

What are the key claims asserted in U.S. Patent No. 8,450,306?

The asserted claims of U.S. Patent No. 8,450,306 are directed to specific extended-release (ER) formulations comprising phentermine and topiramate. Examples of claim limitations relevant to the litigation include:

• Dosage Form: An oral dosage form.
• Active Ingredients: Phentermine and topiramate.
• Release Profile: Specific dissolution rates and pharmacokinetic profiles. For instance, claims often describe the percentage of drug released at various time points.
• Excipients: Specific combinations of inactive ingredients, such as polymers, binders, and disintegrants, used to achieve the desired extended-release properties.

For example, Claim 1 of the '306 patent generally recites an oral dosage form comprising:

1. Phentermine free base.
2. Topiramate.
3. A polymer selected from a specific group (e.g., hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), ethylcellulose).
4. A plasticizer.
5. And potentially other components designed to control drug release.

The precise wording of each asserted claim and its interpretation by the court were critical to the infringement analysis.

How did the court interpret the "extended-release" aspect?

The interpretation of "extended-release" was central to the non-infringement finding. The court examined the specific parameters defining the extended-release profile as claimed in the patent, such as:

• Dissolution Testing: The rate at which the active ingredients dissolve in vitro under specified conditions. Patent claims often define release percentages at different time points (e.g., 2 hours, 8 hours, 12 hours).
• Pharmacokinetic (PK) Parameters: In vivo drug absorption characteristics, such as the time to reach maximum concentration (Tmax) and the overall absorption profile.

The court found that Actavis's proposed generic formulation did not meet the specific dissolution or PK profiles claimed by VIVUS. This divergence meant that Actavis's product was outside the scope of the patent's claims, even if it contained the same active ingredients and generally provided extended release.

What were the specific findings regarding enablement?

The court found certain claims of the '306 patent to be invalid for lack of enablement. Enablement requires that a patent disclosure be sufficiently detailed to teach a person of ordinary skill in the art how to make and use the claimed invention without undue experimentation.

The court's enablement analysis likely focused on whether the patent adequately described how to achieve the specific extended-release properties claimed, given the range of formulation variables and excipients. If the patent did not provide sufficient guidance for a skilled artisan to reliably produce the claimed formulations, those claims could be deemed not enabled.

What is the significance of this litigation for other patent disputes?

The VIVUS v. Actavis litigation underscores several important principles in pharmaceutical patent litigation:

• Claim Specificity: The case demonstrates the critical importance of precisely defining the claimed invention in patent applications. Broadly defined claims are more susceptible to invalidity challenges, while overly narrow claims may not capture the full scope of the innovation or prevent competitors from designing around them.
• Formulation-Based Patents: Litigation involving formulation patents often hinges on detailed technical arguments about dissolution profiles, excipient combinations, and manufacturing processes. Generic challengers must meticulously analyze these aspects to demonstrate non-infringement or invalidity.
• Enablement as a Defense: The successful challenge based on enablement highlights that a patent must not only claim an invention but also teach the public how to practice it. Inadequate disclosure can render claims invalid.
• Strategic Importance of IPRs and Litigation: This case exemplifies how patent litigation, including inter partes review (IPR) proceedings (though not the primary focus here) and district court actions, serves as a crucial mechanism for determining market exclusivity for branded drugs and facilitating the entry of generics.

Key Takeaways

• U.S. Patent No. 8,450,306, covering specific extended-release formulations of phentermine and topiramate for VIVUS's Qsymia, was the subject of litigation.
• The U.S. Court of Appeals for the Federal Circuit affirmed a district court ruling of non-infringement by Actavis's proposed generic product.
• Certain claims of the '306 patent were also found invalid for lack of enablement by the district court and affirmed on appeal.
• These rulings cleared the way for generic versions of Qsymia to enter the market.
• The litigation highlights the importance of precise claim drafting, detailed enablement, and technical analysis in pharmaceutical patent disputes.

FAQs

1. Did VIVUS lose all patent protection for Qsymia? VIVUS's '306 patent faced invalidity and non-infringement challenges. While the patent was the central focus of this particular litigation, other potential patent protection for Qsymia might exist. However, the invalidation and non-infringement of the '306 patent significantly impacted its market exclusivity.

2. What specific technical arguments led to the non-infringement finding? The non-infringement finding was based on the court's determination that Actavis's proposed generic formulation did not meet the specific limitations of the asserted claims of the '306 patent, particularly concerning the defined extended-release profiles (dissolution rates and pharmacokinetic parameters) and potentially the specific combinations of excipients claimed.

3. What is the legal standard for "enablement" in patent law? Enablement requires that a patent disclosure teach a person of ordinary skill in the art how to make and use the full scope of the claimed invention without undue experimentation. If the disclosure is insufficient, the patent claims can be invalidated.

4. How does this litigation affect the price of Qsymia or its generic equivalents? Patent litigation that results in a finding of non-infringement or invalidity typically leads to the introduction of generic competition. Generic drugs are generally priced lower than their branded counterparts, which would lead to a decrease in the overall cost of treatment for the active ingredients.

5. Were there any other significant patents involved in protecting Qsymia? While the '306 patent was the primary patent litigated against Actavis in this specific case (2:14-cv-03786), pharmaceutical companies often hold multiple patents covering different aspects of a drug, including different formulations, methods of use, or manufacturing processes. The extent of Qsymia's remaining patent protection would depend on the status of these other patents.

Citations

[1] United States Court of Appeals for the Federal Circuit. (2016). VIVUS, Inc. v. Actavis Laboratories FL, Inc. No. 2015-1515.